{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-005104","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.914527+00:00","generated_at":"2026-05-28T01:57:55.329758+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sight Sciences prelim Q4 2024 rev $18.9-19.1M (+1% YoY); Surgical Glaucoma +9%","bullets":["Surgical Glaucoma revenue $18.7-18.8M (+9% YoY at midpoint); Dry Eye rev $0.2-0.3M vs $1.6M prior year.","Full year 2024 total revenue $79.7-79.9M (-2% YoY); cash and equivalents ~$120M; $1.4M generated in Q4.","New LCDs by five Medicare contractors effective mid-November restricted MIGS coverage, impacting results.","Company plans to achieve cash flow breakeven without additional equity capital; FY 2024 cash used $18.1M down from $46.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-005104","json":"https://secwatch.observer/filing/0000950170-25-005104.json","markdown":"https://secwatch.observer/filing/0000950170-25-005104.md","text":"https://secwatch.observer/filing/0000950170-25-005104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017025005104/0000950170-25-005104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017025005104/sght-20250114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:57:55.329758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}